Results 201 to 210 of about 29,720,759 (240)

Update on efficacy, safety, and immunogenicity of Dengue vaccines: a systematic review and meta-analysis. [PDF]

Infez Med
Zaçe D, Çekrezi A, Leone M, Ciarpaglini S, Montagnari G, Giacalone ML, Diforti S, Rodriguez-Morales AJ, Iannetta M, Sarmati L.   +9 more
europepmc   +1 more source

Molecular and biophysical requirements for B cell receptor-dependent enhancement of dengue virus infection. [PDF]

J Virol
Madrigal G, Gebo C, McElvany BD, Symeonides M, Diehl SA, Waickman AT.   +5 more
europepmc   +1 more source

Dengue vaccines: The role of a correlate of protection in evaluating vaccine safety and risk. [PDF]

Vaccine
Wong JM, Acevedo PK, Whitehead S, Durbin A, DeSale H, Jones FK, Medina FA, Rovira-Diaz E, Prutzman K, Leao IC, Wang T, Desilva A, Harris E, Katzelnick L, Salje H, Weiskopf D, Adams LE, Paz-Bailey G.   +17 more
europepmc   +1 more source

Prevalence of neutralizing autoantibodies against type I interferon in dengue patients. [PDF]

J Hum Immun
Yang M, Liao Y, Yang X, Fan J, Liao M, Wu Y, Yang H, Wang J, Zhang W, Li F, Yu H, Ling Y.   +11 more
europepmc   +1 more source

XPO1-dependent nuclear export regulates NS3 localization and promotes DENV-2 replication through mitochondrial remodeling and interferon suppression. [PDF]

Nucleus
Palacios-Rápalo SN, Hernández-Castillo J, De Jesús-González LA, Talamas-Lara D, Cordero-Rivera CD, Cisneros-Vega B, Reyes-Ruiz JM, María Del Ángel R.   +7 more
europepmc   +1 more source

Antibody Responses in Pediatric Dengue Indicate Emergence and Co-Circulation of DENV-3 Genotypes I and III in Myanmar and Orthoflavivirus Cross-Reactivity. [PDF]

J Med Virol
Balingit JC, Nwe KM, Lin H, Aung WW, Suzuki R, Takamatsu Y, Urano T, Khin AA, Thant KZ, Thu HM, Ngwe Tun MM, Morita K.   +11 more
europepmc   +1 more source

Marine-Derived Natural Products Against Flaviviruses: Mechanisms, Evidence, and Future Directions. [PDF]

Mar Drugs
Park HS, Heo MS, Kwon HN, Jang YH, Bae M, Kwon Y.   +5 more
europepmc   +1 more source

A novel method for depletion of dengue virus non-structural protein 1 antibodies to determine serotype exposure history. [PDF]

mSphere
Zheng YY, Morwitzer MJ, McCracken MK, Friberg H, Gromowski GD, Currier JR.   +5 more
europepmc   +1 more source

New Insights Into an Old Vaccine: Potency and Breadth of Neutralizing Antibodies Elicited by Yellow Fever Vaccine 17D Are Boosted by Heterologous Orthoflavivirus Infection. [PDF]

J Infect Dis
Coulter FJ, Micheletti CA, Estrada AE, Luo S, Osman SR, Nix CD, Hu SY, Sampouw SM, Kareko BW, Naleway AL, Messer WB.   +10 more
europepmc   +1 more source

Mapping immune responses to TAK-003 dengue vaccine: immunogenicity across the clinical development program. [PDF]

Front Immunol
Mandaric S, El Hindi T, Nascimento EJM, Saez-Llorens X, Borja-Tabora C, Friberg H, Tricou V, Roubinis N, Gottardo R, Currier JR, Sharma M, Biswal S.   +11 more
europepmc   +1 more source